HTR3A and cancer: According to the Multinational Association of Supportive Care in Cancer (MASCC) guidelines, SG is labeled as moderately emetogenic with an asterisk, indicating it is high–moderate, resembling the carboplatin area under the curve (AUC) > 5 [41]; therefore, a three-drug regimen with dexamethasone, a 5-hydroxytryptamine (5HT3 or serotonin) receptor antagonist (RA), and a neurokinin 1 (NK1) RA is recommended [42].